Advanced Respiratory Therapy Novel DPP-4 Inhibitor Composition Targets Respiratory Diseases

Chronic respiratory diseases like asthma, bronchiectasis, and chronic obstructive pulmonary disease (COPD) affect hundreds of millions of people globally and represent a leading cause of mortality. Current treatment approaches address symptoms and underlying inflammation but often result in suboptimal control and significant quality-of-life impacts. This patent describes pharmaceutical compositions containing a novel compound that inhibits dipeptidyl peptidase-4 (DPP-4), an enzyme involved in multiple physiological processes. By blocking DPP-4 activity, the formulation addresses respiratory disease mechanisms in ways complementary to existing therapies, offering potential for improved disease management and expanded treatment options.

The Problem

Respiratory diseases represent a substantial and growing global health burden. COPD alone affects over 400 million people worldwide and is a leading cause of death and disability. Asthma affects over 300 million people. These conditions involve complex physiological mechanisms including inflammation, airway remodeling, and immune dysfunction. Existing treatments-including corticosteroids, bronchodilators, and leukotriene modifiers-address specific aspects of disease but often prove inadequate for complete disease control.

The challenge in respiratory drug development is that these diseases involve multiple interrelated mechanisms. Blocking any single pathway rarely achieves complete disease resolution. Combination therapies are common but create additional complexity and side effects. The field actively seeks novel compounds that address respiratory disease mechanisms through different pharmacological approaches, offering either monotherapy benefits or enhanced combination therapy effects.

Dipeptidyl peptidase-4 (DPP-4) has been studied for its roles in immune function, metabolism, and inflammation. The enzyme cleaves and inactivates multiple peptides involved in immune response and inflammatory processes. Inhibiting DPP-4 could potentially enhance immune function or reduce excessive inflammatory responses, making it a rational enzyme inhibitor target, making it a rational target for respiratory disease. However, developing an effective DPP-4 inhibitor with appropriate pharmacological properties for respiratory application has proven challenging.

What This Invention Does

This patent describes pharmaceutical compositions containing (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide, referred to as “Compound A,” or pharmaceutically acceptable salts thereof. Compound A is a DPP-4 inhibitor designed specifically for respiratory disease treatment.

The patent describes pharmaceutical compositions suitable for oral administration, including tablet formulations that enable convenient patient dosing. The compositions address the challenge of delivering Compound A in a stable, bioavailable, and patient-acceptable form.

The invention specifies that Compound A inhibits DPP-4 (EC 3.4.14.1) and has been studied for treating and preventing clinical conditions including respiratory diseases-specifically asthma, bronchiectasis, and chronic obstructive pulmonary disease (COPD). The compound’s mechanism-DPP-4 inhibition-offers a physiological approach to these diseases that complements existing treatment mechanisms.

Key Features

Dual Respiratory Applications. Compound A is applicable to both acute conditions like asthma exacerbations and chronic progressive diseases like COPD and bronchiectasis, potentially offering broader therapeutic utility than agents targeting single disease forms.

Novel Mechanism. DPP-4 inhibition represents a distinct pharmacological approach compared to corticosteroids, bronchodilators, and other existing respiratory drugs, offering potential for combination therapies or monotherapy in patients not adequately controlled by conventional treatments.

Oral Bioavailability. The pharmaceutical compositions enable oral dosing, the preferred route for chronic disease management, avoiding the complexity of inhaled or parenteral administration required by some respiratory treatments.

Improved Tolerability Profile. By targeting a specific enzyme mechanism rather than broadly suppressing inflammation or neural activity, DPP-4 inhibition potentially offers improved tolerability compared to some conventional respiratory drugs.

Stable Formulations. The patent describes tablet compositions that remain stable through manufacturing, storage, and transport, enabling practical pharmaceutical distribution.

Who Is Behind It?

AstraZeneca AB, headquartered in Sweden and one of the world’s largest pharmaceutical companies, developed this compound with three inventors: Hakan Wikstrom, Jufang Wu Ludvigsson, and Thomas Andersson. The patent references earlier disclosures of Compound A in U.S. Patent Publication 2015/0210655, indicating years of development preceding this formulation patent. This represents a divisional application from an earlier patent (2024220121), suggesting progressive refinement of compositions and claims around Compound A.

Why It Matters

Respiratory diseases represent an enormous pharmaceutical market. Global spending on respiratory disease treatments exceeds 60 billion dollars annually, with COPD and asthma driving the largest segments. Any novel compound demonstrating efficacy in respiratory disease management has substantial commercial potential.

Beyond the market, respiratory diseases cause enormous human suffering. Patients with uncontrolled COPD experience progressive disability, repeated hospitalizations, and shortened lifespans. Those with severe asthma face constant threat of life-threatening exacerbations. Patients with bronchiectasis experience chronic productive cough and progressive lung damage. Novel treatment approaches offering disease modification or improved control would meaningfully improve patients’ lives.

Particularly for COPD, current therapies have reached a plateau in efficacy. Most patients benefit from existing medications, but complete disease control remains elusive for many. A novel mechanism like DPP-4 inhibition that addresses different physiological pathways could unlock treatment benefits in patients who’ve exhausted conventional options.

The DPP-4 enzyme has multiple physiological roles beyond respiratory disease, suggesting Compound A might have applications in other diseases as well. However, the focus on respiratory conditions in this patent reflects the specific unmet need and market opportunity in that therapeutic area.

The IPC classifications (A61K 31/553, A61P 11/06) confirm this is recognized as a significant innovation in pharmaceutical chemistry and respiratory disease treatment, reflecting the clinical importance and technical achievement of the compound development.

---

AU 2026201419 was published in the Australian Official Journal of Patents on 19 March 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.

Related Concepts

Dipeptidyl peptidase-4 (DPP-4) is best known as a target in type 2 diabetes treatment, where DPP-4 inhibitors (gliptins) are widely prescribed. Its emerging role in respiratory inflammation represents a novel area of investigation. Current standard therapies for COPD and asthma – including corticosteroids and bronchodilators – address symptoms but rarely halt disease progression, underscoring the need for novel mechanistic approaches.